Valneva (VALN) has released an update.
Valneva SE has reported steady financial results for the first half of 2024, with total revenues of €70.8 million and a net profit of €34.0 million, reflecting a strong recovery from the previous year’s losses. The company has confirmed its full-year revenue guidance, expecting between €170 million and €190 million, and has successfully expanded its strategic pipeline, including the acquisition of an exclusive license for a Phase 2 Shigella vaccine candidate. Moreover, Valneva’s chikungunya vaccine, IXCHIQ®, is gaining traction with new authorizations in Europe and Canada and anticipated label expansions.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
